Last reviewed · How we verify

OxThera — Portfolio Competitive Intelligence Brief

OxThera pipeline: 0 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 1 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Oxabact OC5 - Oxalobacter formigenes HC-1 Oxabact OC5 - Oxalobacter formigenes HC-1 phase 3 Live biotherapeutic product Nephrology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ardeypharm GmbH · 1 shared drug class
  2. Fondazione Policlinico Universitario Agostino Gemelli IRCCS · 1 shared drug class
  3. Infant Bacterial Therapeutics · 1 shared drug class
  4. Mikrobiomik Healthcare Company S.L. · 1 shared drug class
  5. Rebiotix Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for OxThera:

Cite this brief

Drug Landscape (2026). OxThera — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/oxthera. Accessed 2026-05-14.

Related